The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study

Simple item page
dc.contributor.authorAlmuradova, E
dc.contributor.authorSeyyar, M
dc.contributor.authorArak, H
dc.contributor.authorTamer, F
dc.contributor.authorKefeli, U
dc.contributor.authorKoca, S
dc.contributor.authorSen, E
dc.contributor.authorTelli, TA
dc.contributor.authorKaratas, F
dc.contributor.authorGokmen, I
dc.contributor.authorTurhal, NS
dc.contributor.authorSakalar, T
dc.contributor.authorAyhan, M
dc.contributor.authorEkinci, F
dc.contributor.authorHafizoglu, E
dc.contributor.authorKahraman, S
dc.contributor.authorKesen, O
dc.contributor.authorUnal, C
dc.contributor.authorAlan, O
dc.contributor.authorCelik, S
dc.contributor.authorYekeduz, E
dc.contributor.authorOmur, O
dc.contributor.authorGokmen, E
dc.date.accessioned2025-04-10T10:37:15Z
dc.date.available2025-04-10T10:37:15Z
dc.description.abstractMetastatic castration-resistant prostate cancer (mCRPC) remains a challenging condition to treat despite recent advancements. This retrospective study aimed to assess the activity and tolerability of Lutetium-177 (Lu-177) PSMA-617 radioligand therapy (RLT) in mCRPC patients across multiple cancer centers in Turkey. The study included 165 patients who received at least one cycle of Lu-177 PSMA-617 RLT, with the majority having bone metastases and undergone prior treatments. Prostate-specific antigen (PSA) levels were assessed before each treatment cycle, and the biochemical response was evaluated in accordance with the Prostate Cancer Work Group 3 Criteria. The PSA decline of >= 50% was classified as a response, while an increase of >= 25% in PSA levels was indicative of progressive disease. Neither response nor progression was considered as stable disease. The Lu-177 PSMA-617 RLT led to a significant PSA response, with 50.6% of patients achieving a >50% decrease in PSA levels. Median overall survival (OS) and progression-free survival were 13.5 and 8.2 months, respectively. Patients receiving Lu-177 PSMA-617 RLT in combination with androgen receptor pathway inhibitors (ARPIs) had a higher OS compared to those receiving Lu-177 PSMA-617 RLT alone (18.2 vs 12.3 months, P = .265). The treatment was generally well-tolerated, with manageable side effects such as anemia and thrombocytopenia. This study provides real-world evidence supporting the effectiveness and safety of Lu-177 PSMA-617 RLT in mCRPC patients, particularly when used in combination with ARPIs. These findings contribute to the growing body of evidence on the potential benefits of PSMA-targeted therapies in advanced prostate cancer.
dc.identifier.e-issn1097-0215
dc.identifier.issn0020-7136
dc.identifier.urihttp://hdl.handle.net/20.500.14701/42927
dc.language.isoEnglish
dc.titleThe real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu